RAD ONC FREEDOM Oncology Pain
ConditionCancer Pain
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorJonsson Comprehensive Cancer Center
About this trial
The investigators propose to conduct a study in medically refractory cancer pain patients utilizing radiosurgery to ablate the pituitary hypophysis, as well as neuromodulate the centromedian and parafascicular complexes within the thalami - the so-called triple target. This involves treating the pituitary hypophysis and thalamus to a dose of 90 Gy. These patients will have previously failed to achieve adequate pain control with opioid pain regimens and interventional approaches. The trial will involve a multidisciplinary approach involving radiation oncology, neurosurgery, palliative care, and medical oncology colleagues across UCLA.
Eligibility criteria
Qualifiers
Male or female ≥ 18 years of age on day of SRS treatment.
Documentation of insufficiently controlled mixed, complex cancer pain based on Brief Pain Inventory (BPI) >8/10 despite optimization of opioid regimen
Not eligible for or willing to undergo further pain-relieving interventions
Written informed consent (and assent when applicable) obtained from patient or patient's legal representative and ability for patient to comply with the study requirements and agree to undergo the study's SRS treatment plan.
Disqualifiers
Pregnant, breastfeeding, or unwilling to practice birth control during participation in the study.
Claustrophobia or inability to life flat
Inability to undergo routine imaging studies
Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.
Trial design
Treatments tested in this trial
- Radiosurgery
Treatment groups
19 Participants
are divided into 1 treatment groupSponsors and collaborators
Jonsson Comprehensive Cancer Center
Lead sponsor
Brainlab AG
Collaborator
Source ClinicalTrials.gov